Plain-English translation of NCT07369492 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new treatment called for adults with a type of blood cancer (B-cell lymphoma) that has not responded to standard treatments. The medication is made by taking your own immune cells, modifying them in the laboratory to recognize and attack cancer cells, and then putting them back into your body. Researchers want to find out if this treatment is safe and effective, and to figure out the best dose to use.
Most people with B-cell lymphoma respond well to standard chemotherapy, but some patients' cancers stop responding or come back. For these patients, there are very few good options left. This trial is exploring whether this new cell-based approach could offer hope to people whose cancers are no longer controlled by conventional treatments.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would first receive chemotherapy (fludarabine and cyclophosphamide) to prepare your body for the treatment. Your own immune cells would then be collected, sent to a laboratory where they are modified to recognize your cancer, grown in larger numbers, and infused back into your body. You would be closely monitored for safety, with regular blood tests, imaging scans, and clinic visits to track how your body responds and whether your cancer improves. The study is designed to test three different dose levels to find the safest and most effective amount.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
China
Phase
Safety & dosing
Sponsor
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Enrollment target
~30 participants
Started
January 2026
Primary completion
January 2027
Age range
18 Years and older
Last updated on clinicaltrials.gov in February 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Xiao Ma
Jiangsu Topcel-KH Pharmaceutical Co., Ltd.
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.